PBD Biotech, based in Thurston, UK, has developed Actiphage, a sensitive diagnostic test that detects live mycobacterial bacteria in blood, milk or other tissue in as little as six hours. Actiphage can also distinguish between infected and vaccinated animals, and holds UK Government approval for chronic herd breakdowns. The company was set up just over 12 months prior to the article and is currently conducting multiple field-based trials. PBD intends to use newly raised capital to fund international trials and to launch a suite of products. Backers include New Anglia Capital, regional investment groups and individual angel investors including farmers and vets. The business is positioning its rapid-test technology for wider commercial and international deployment through these trials and product launches.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2018